Senti Bioscience Stock Price, News & Analysis

Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company focused on developing a new generation of cell and gene therapies for patients living with incurable diseases. According to the company, its approach centers on a synthetic biology platform that engineers Gene Circuits into medicines to provide enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target tissues, and in some cases be controllable even after administration.

Senti Bio’s work is grounded in the concept that cell and gene therapies can be programmed with logic-like functions. The company describes Gene Circuits that have been shown preclinically to function in both natural killer (NK) cells and T cells, and notes that it has also demonstrated preclinical potential for Gene Circuits in other modalities and in diseases outside of oncology. The company’s wholly owned pipeline, as described in its public communications, is comprised of cell therapies engineered with Gene Circuits that are intended to address challenging liquid and solid tumor indications.

Core focus: Logic Gated cell therapies

A central element of Senti Bio’s strategy is the development of Logic Gated cell therapies. These therapies are designed so that engineered cells respond to combinations of molecular signals, enabling selective cancer cell killing while protecting normal tissues. Senti Bio highlights this approach in its lead program, SENTI-202, which it describes as a first-in-class, off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate.

Public disclosures describe SENTI-202 as a Logic Gated CAR-NK therapy targeting hematologic malignancies that express CD33 and/or FLT3, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Senti Bio states that SENTI-202 is being evaluated in an ongoing Phase 1, multinational, multicenter clinical trial in adult patients with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including AML.

SENTI-202: Design and mechanism

According to the company’s descriptions, SENTI-202 incorporates three main Gene Circuit components:

• OR GATE: An activating CAR designed to recognize and kill CD33 and/or FLT3 expressing cells. By targeting either or both of these antigens, SENTI-202 is intended to attack leukemic blasts, which largely express CD33, and leukemic stem cells, which predominantly express FLT3.
• NOT GATE: An inhibitory CAR designed to recognize EMCN (endomucin), which Senti Bio describes as selectively expressed on healthy hematopoietic stem and progenitor cells (HSPCs). This NOT GATE is intended to protect those healthy cells from being killed even if they express CD33 and/or FLT3, thereby potentially widening the therapeutic window.
• Calibrated-release IL-15: A component designed to significantly increase cell persistence, expansion, and activity of both the CAR-NK cells and host immune cells.

The NK cells used to construct SENTI-202 are described as being sourced from selected healthy adult donors, manufactured, cryopreserved, and made available off-the-shelf for use as needed. Senti Bio positions SENTI-202 as a potential first-in-class allogeneic treatment option for patients with AML and MDS whose disease expresses CD33 and/or FLT3.

Regulatory designations and clinical-stage status

Senti Bio characterizes itself as a clinical-stage biotechnology company. Public announcements indicate that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of relapsed or refractory hematologic malignancies including AML. The company states that these designations were supported by preliminary clinical evidence from its ongoing Phase 1 trial and are intended to facilitate interactions with the FDA and potentially expedite development and review.

In its communications around scientific meetings such as the American Society of Hematology (ASH) Annual Meeting, Senti Bio has highlighted clinical and pharmacodynamic data from SENTI-202. The company reports that these data support the proposed Logic Gate mechanism of action, including selective killing of AML blasts and leukemic stem cells while sparing healthy hematopoietic stem and progenitor cells in the bone marrow.

Pipeline and platform breadth

Beyond SENTI-202, Senti Bio describes a wholly owned pipeline of cell therapies engineered with Gene Circuits to target difficult liquid and solid tumor indications. While detailed program lists are not provided in the supplied materials, the company repeatedly emphasizes that its Gene Circuits have been shown preclinically to function in both NK and T cells. It also notes preclinical work demonstrating potential applications of Gene Circuits in other therapeutic modalities and in diseases outside oncology, which it is advancing in part through partnerships.

This focus on a programmable Gene Circuit platform underpins Senti Bio’s positioning within the broader field of cell and gene therapy. Rather than describing single-target constructs alone, the company emphasizes the ability of its circuits to incorporate multiple inputs and outputs—such as OR and NOT logic gates and cytokine expression—to shape therapeutic activity.

Industry classification and listing

For industry classification purposes, Senti Biosciences, Inc. is associated with biological product manufacturing within the broader manufacturing sector. The company’s stock trades on Nasdaq under the ticker symbol SNTI. SEC filings identify Senti Biosciences, Inc. as an emerging growth company, and list its principal executive offices in South San Francisco, California.

Corporate and investor communications

Senti Bio regularly issues press releases and SEC filings that provide updates on its clinical programs, financial position, and corporate activities. Recent disclosures include quarterly financial results, participation in scientific and investor conferences, and announcements related to regulatory designations and clinical data for SENTI-202. The company also notes that it advances aspects of its Gene Circuit platform and non-oncology applications through partnerships.

Because Senti Bio remains in the clinical stage, its publicly available information focuses on research and development progress, regulatory interactions, and early clinical findings rather than commercial product revenues. Investors and observers typically follow updates on the SENTI-202 program, platform developments, and the evolution of its pipeline as key indicators of the company’s trajectory within the cell and gene therapy field.

FAQs about Senti Biosciences, Inc. (SNTI)

• What does Senti Biosciences, Inc. do?
  Senti Biosciences, Inc. is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. These circuits are designed to enable precise cancer cell killing, protection of healthy cells, and improved control over therapeutic activity.
• What is Senti Bio’s main therapeutic focus?
  Based on its public statements, Senti Bio’s primary focus is on oncology, particularly liquid and solid tumor indications. Its lead program, SENTI-202, targets relapsed or refractory hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome that express CD33 and/or FLT3.
• How does Senti Bio’s Gene Circuit platform work?
  The company describes its Gene Circuit platform as a synthetic biology approach that programs cells with logic-like functions. In SENTI-202, for example, OR and NOT logic gates and calibrated-release IL-15 are combined to selectively kill cancer cells expressing CD33 and/or FLT3 while sparing healthy hematopoietic stem and progenitor cells that express EMCN.
• What is SENTI-202?
  SENTI-202 is Senti Bio’s lead product candidate, described as a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy. It is designed to target CD33 and/or FLT3 expressing hematologic malignancies, such as AML and MDS, while sparing healthy bone marrow cells, and is being evaluated in an ongoing Phase 1 clinical trial.
• Has SENTI-202 received any FDA designations?
  According to company announcements, the U.S. Food and Drug Administration has granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of relapsed or refractory hematologic malignancies including AML.
• What cell types does Senti Bio use in its therapies?
  Senti Bio reports that its Gene Circuits have been shown preclinically to work in both NK and T cells. SENTI-202 specifically uses NK cells sourced from selected healthy adult donors, which are manufactured, cryopreserved, and provided as off-the-shelf allogeneic cell therapy.
• Is Senti Bio generating commercial revenue from approved products?
  The information provided describes Senti Bio as a clinical-stage biotechnology company, with disclosures focused on research, development, and clinical trials rather than on approved commercial products.
• Where is Senti Biosciences, Inc. based and how is it listed?
  SEC filings list Senti Biosciences, Inc.’s principal executive offices in South San Francisco, California. The company’s common stock is listed on Nasdaq under the ticker symbol SNTI.